Latest Content

Venclexta With a Hypomethylating Agent Shows Promise for Patients with Acute Myeloid Leukemia

May 6th 2021, 9:00pm

By Colleen Moretti

Article

Compared to a hypomethylating agent alone, combining the agent with Venclexta improved complete remission rates in patients with blast-phase myeloproliferative neoplasm.

FDA Committee Recommends Continuing Accelerated Approval Status of Tecentriq in Certain Patients with Metastatic Triple-Negative Breast Cancer

May 6th 2021, 6:00pm

By Ryan McDonald

Article

Members of an FDA committee voted in favor of Tecentriq plus Abraxane keeping its accelerated approval for the treatment of adults with unresectable, locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1.

When Oncologists Retire, Their Patients Must Learn to Embrace Change

May 6th 2021, 4:00pm

By Kelly Irvin

Article

“We’re all blessed that there are so many dedicated, caring health care professionals willing to step in and fill the void when members of the team move or retire,” writes a patient with cancer. “We can never forget how tough a gig it is or say thank you enough.”

A Prostate Cancer Researcher’s Unique Perspective as A Cancer Survivor

May 6th 2021, 3:00pm

By Jamie Cesanek

Podcast

In this episode of the “CURE® Talks Cancer” podcast, Leanne Burnham, Ph.D., discusses the research she’s working on to address health disparities in Black men with prostate cancer after being inspired by her father’s diagnosis, and shares her own cancer survival story.

FDA Grants Keytruda-Lenvima Combo Priority Review for Treatment of Advanced Kidney Cancer and Endometrial Cancer

May 6th 2021, 1:52pm

By Ryan McDonald

Article

The priority review will focus on the combination of Keytruda and Lenvima for the first-line treatment of advanced renal cell carcinoma, as well as the treatment of certain patients with endometrial carcinoma.

Nurse Finds ‘Silver Lining’ for Survivors of Cancer with Virtual Visits

May 6th 2021, 1:00pm

By Colleen Moretti

Article

Virtual visits during the COVID-19 pandemic improved satisfaction and convenience, as well as reduced stress and anxiety in veterans who have survived cancer.

FDA Panel Votes in Favor of Upholding Tecentriq’s Indication in First-Line Treatment of Bladder Cancer

May 5th 2021, 9:00pm

By Ryan McDonald

Article

FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.

FDA Approves Keytruda for Use With Trastuzumab and Chemotherapy for Subtypes of Stomach Cancer

May 5th 2021, 6:58pm

By Darlene Dobkowski, MA

Article

Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.

Unhealthy Habits May Increase in Some Women After a Breast Cancer Diagnosis

May 5th 2021, 6:00pm

By Colleen Moretti

Article

Women who receive a breast cancer diagnosis were more likely to develop unhealthy behaviors one and two years after diagnosis, even if they were considered healthy at time of diagnosis.

How Blizzards and Cancer Are Similar

May 5th 2021, 4:00pm

By Jane Biehl Ph.D.

Article

A cancer survivor recalls how a book quote about a blizzard became a metaphor for her own experiences with cancer.

Risk of COVID-19 'Far Outweighs' Rare Blood Clot Risk from J&J Single-Dose Vaccine in Patients with Cancer

May 5th 2021, 3:00pm

By Jamie Cesanek

Article

Patients with cancer should receive whichever COVID-19 vaccine is made available to them as the benefits far outweigh the risks, according to an expert from Memorial Sloan Kettering Cancer Center.

Tecartus May Contribute to Long-Term Responses in Relapsed/Refractory Mantle Cell Lymphoma

May 5th 2021, 1:00pm

By Darlene Dobkowski, MA

Article

Factors including progression-free survival, duration of response and overall survival were promising at 15 months in patients with relapsed/refractory mantle cell lymphoma.

Most Patient Records Within A Large Cancer Registry-Based Real-World Data Source Have Missing Data

May 4th 2021, 9:00pm

By Jamie Cesanek

Article

A significant number of patient records in large cancer registries are missing data, which can have an impact on real-world data studies.

More Research Needed to Identify if Medical Marijuana Effectively Reduces Common Chemotherapy Side Effects

May 4th 2021, 6:00pm

By Ryan McDonald

Article

There is some low-level evidence that suggests medical marijuana or cannabinoids may reduce chemotherapy-related side effects in patients with cancer, according to data presented at a recent medical conference. However, experts note more research is needed to build on those findings.

A Bucket List? Even A Poor Guy Like Me Can Dream!

May 4th 2021, 4:00pm

By Ron Cooper

Article

A cancer survivor recalls how he never considered a bucket list until his diagnosis in 2014. And although he knows he can’t afford to buy a Ferrari and cruise through the Alps, he’s OK with changing course and going with something much smaller.